NALIRIFOX Versus FOLFOX as First-oLine Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): Real-World Comparative Overall (OS) Survival Analysis

被引：0
|
作者：
O'Reilly, Eileen [1 ]
Li, Jia [2 ]
DerSarkissian, Maral [3 ]
Chang, Rose [4 ]
Cheng, Mu [4 ]
Yu, Louise [4 ]
Rane, Deepali [2 ]
Zhang, Li [2 ]
Xiao, Zhimin [2 ]
Benzaghou, Fawzi [5 ]
Duh, Mei Sheng [4 ]
Chen, Huanyu [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Ipsen Corp, Paris, France
[3] Anal Grp Inc, Los Angeles, CA USA
[4] Anal Grp Inc, Boston, MA USA
[5] IPSEN, Paris, France
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
442
引用
收藏
页码：176 / 176
页数：1
相关论文
共 50 条
  • [21] Multivariable analysis of real-world clinical outcomes associated with dose reductions (DRs) for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan
    Abushahin, L.
    Cockrum, P.
    Surinach, A.
    Belanger, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S943 - S944
  • [22] Real-world treatment discontinuation patterns among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
    Kim, G.
    Surinach, A.
    Wang, S.
    Lamarre, N.
    Cockrum, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1107 - S1108
  • [23] Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as second-line treatment for advanced pancreatic adenocarcinoma: A real-world analysis
    Tezuka, Shun
    Ueno, Makoto
    Kobayashi, Satoshi
    Morimoto, Manabu
    Nagashima, Shuhei
    Sano, Yusuke
    Asama, Hiroyuki
    Kawano, Kuniyuki
    Tanaka, Satoshi
    Fukushima, Taito
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [24] Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
    Kim, G.
    Cockrum, P.
    Surinach, A.
    Wang, S.
    Lamarre, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S1092 - S1093
  • [25] REAL-WORLD "CHAIR-TIME" BURDEN ASSOCIATED WITH INTRAVENOUS TREATMENT REGIMENS FOR PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
    MacEwan, J.
    Surinach, A.
    Lamarre, N.
    Cockrum, P.
    VALUE IN HEALTH, 2022, 25 (07) : S326 - S326
  • [26] Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.
    Taieb, Julien
    Hammel, Pascal
    Reni, Michele
    Palmer, Daniel H.
    Bridgewater, John A.
    Cubillo, Antonio
    Prager, Gerald W.
    Vermeire, Alice
    D'Esquermes, Nathalie
    Biville-Hedouin, Fabienne
    Teng Zhaoyang
    Seufferlein, Thomas
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [27] Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: Univariate and multivariate analyses of a real-world study in Europe
    Taieb, J.
    Hammel, P.
    Reni, M.
    Palmer, D.
    Bridgewater, J.
    Cubillo, A.
    Prager, G.
    Bayle, S.
    Teng, Hedouin-Biville Z.
    Teng, Z.
    Seufferlein, T.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S203 - S203
  • [28] NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem plus NabP) in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Subgroup analysis of patients aged 65 years or older in NAPOLI 3
    Macarulla Mercade, T.
    Pazo Cid, R. A.
    Womack, M.
    Cubillo Gracian, A.
    Zervoudakis, A.
    Hatoum, H.
    Chung, V.
    Patel, A.
    Paulson, A. S.
    Pant, S.
    O'Reilly, E. M.
    Hubner, R.
    Van Cutsem, E.
    Bekaii-Saab, T.
    Zhang, L.
    Li, J.
    Chen, H.
    Maxwell, F.
    Wainberg, Z. A.
    Melisi, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S135 - S136
  • [29] Real-world data comparing FOLFIRINOX versus gemcitabine nab-paclitaxel as first-line treatment of metastatic pancreatic ductal adenocarcinoma patients in the United States.
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric Andrew
    Fisch, Michael Jordan
    Aran, Dvir
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16271 - E16271
  • [30] Clinical pathway implications and real-world characteristics and outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first line category 1 National Comprehensive Cancer Network (NCCN) regimens
    Kim, G.
    Cockrum, P.
    Arndorfer, S.
    Surinach, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S953 - S954
12345